Current status of radiation therapy and combined-modality treatment for bladder cancer

Strahlentherapie und Onkologie

Volumn 180, Issue 11, 2004, Pages 701-709

  Rödel, Claus ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bladder cancer; Combined modality treatment; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; VINBLASTINE;

ACUTE TOXICITY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CYSTECTOMY; FEASIBILITY STUDY; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; METASTASIS; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PRESCRIPTION; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SALVAGE THERAPY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR LOCALIZATION; URETER OBSTRUCTION;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYSTECTOMY; DRUG THERAPY; HUMANS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 11144291099     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-9195-y     Document Type: Review

References (65)

1. Albrecht MR, Zink K, Busch W, et al. Dissection or irradiation of the axilla in postmenopausal patients with breast cancer? Long-term results and long-term effects in 655 patients. Strahlenther Onkol 2002;178:510-6.
2. Arias F, Dominguez MA, Martinez E, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000;47:373-8.
3. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46:Suppl: 585-104.
4. Caffo O, Fellin G, Graffer U, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys 2003;57:1310-6.
5. Cervek J, Cufer T, Zakotnik B, et al. Invasive bladder cancer: our experience with bladder sparing approach. Int J Radiat Oncol Biol Phys 1998;41: 273-8.
6. Chen WC, Liaw CC, Chuang CK, et al. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 2003;56:726-33.
7. Chyle V, Pollack A, Czerniak B, et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 1996;35:281-7.
8. Cohen-Jonathan E, Muschel RJ, McKenna WG, et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 2000;154: 125-32.
9. Cole DJ, Durrant KR, Roberts JT, et al. A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 1992;65:792-8.
10. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901-7.
11. De Neve W, Lybeert ML, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995;36:183-8.
12. Dunst J. Neoadjuvant chemotherapy in bladder cancer. Strahlenther Onkol 2004;180:184.
13. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994;30:261-6.
14. Dunst J, Weigel C, Heynemann H, et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 1999;175:Suppl 3:7-10.
15. Fellin G, Graffer U, Bolner A, et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997;80:44-9.
16. Gerlach B, Audretsch W, Gogolin F, et al. Remission rates in breast cancer treated with preoperative chemotherapy and radiotherapy. Strahlenther Onkol 2003;179:306-11.
17. Given RW, Parsons JT, McCarley D, et al. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995;46:499-504, discussion 505.
18. Goldobenko GV, Matveev BP, Shipilov VI, et al. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol (Mosk) 1991;36:14-6.
19. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-53.
20. Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 1990;65:908-12.
21. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665-72.
22. Harada S, Sato R, Nakamura R, et al. The correlation between spontaneous and radiation-induced apoptosis in T3B bladder cancer (histological grade G3), and the precedence between the two kinds of apoptosis for predicting clinical prognosis. Int J Radiat Oncol Biol Phys 2000;48:1059-67.
23. Henningsohn L, Wijkstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2002;62:215-25.
24. Housset M, Dufour B, Maulard-Durdux C, et al. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 1997;16:319a. abstract.
25. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-7.
26. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022-9.
27. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-6.
28. Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004;22:2540-5.
29. Kob D, Arndt J, Kriester A, et al. Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation. Strahlentherapie 1985;161:673-7.
30. Kuhnt T, Becker A, Pigorsch S, et al. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 2003;179:673-81.
31. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-70.
32. McLaren DB, Morrey D, Mason MD. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol 1997;43: 171-4.
33. Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2001;49:1305-10.
34. Moonen L, van der Voet H, Horenblas S, et al. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1997;37:537-42.
35. Moonen L, van der Voet H, de Nijs R, et al. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 1998;42:525-30.
36. Naslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol 1994;33:397-402.
37. Nichols RC Jr, Sweetser MG, Mahmood SK, et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. Int J Cancer 2000;90:281-6.
38. Peyromaure M, Slama J, Beuzeboc P, et al. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology 2004;63:73-7.
39. Plataniotis G, Michalopoulos E, Kouvaris J, et al. A feasibility study of partially accelerated radiotherapy for invasive bladder cancer. Radiother Oncol 1994;33:84-7.
40. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:267-77.
41. Pos FJ, van Tienhoven G, Hulshof MC, et al. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 2003;68:75-80.
42. Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 1986;12:853-60.
43. Rachbauer F, Sztankay A, Kreczy A, et al. High-dose-rate intraoperative brachytherapy (IOHDR) using flab technique in the treatment of soft tissue sarcomas. Strahlenther Onkol 2003;179:480-5.
44. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-71.
45. Rodel C, Grabenbauer GG, Rödel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
46. Rostom AY, Tahir S, Gershuny AR, et al. Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1996;35:289-92.
47. Rotman M, Aziz H, Porrazzo M, et al. Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion. Int J Radiat Oncol Biol Phys 1990;18:1131-7.
48. Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693-9.
49. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998;40:121-7.
50. Sauer R, Dunst J, Altendorf-Hofmann A, et al. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990;19:687-91.
51. Scholten AN, Leer JW, Collins CD, et al. Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol 1997;43:163-9.
52. Shipley WU, Rose MA, Perrone TL, et al. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 1985;134:679-83.
53. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.
54. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
55. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-67.
56. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-26.
57. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783-90.
58. Varveris H, Delakas D, Anezinis P, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 1997;17:4771-80.
59. Weiss CRC. Die neoadjuvante Chemotherapie vor radikaler Zystektomie verbessert die Prognose beim muskelinvasiven Blasenkarzinom. Konsequenzen für den Radiotherapeuten? Strahlenther Onkol 2004;4:246-7.
60. Yavuz AA, Yavuz MN, Ozgur GK, et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int J Radiat Oncol Biol Phys 2003;56:734-45.
61. Zapatero A, Martin de Vidales C, Marin A, et al. Invasive bladder cancer: a single-institution experience with bladder-sparing approach. Int J Cancer 2000;90:287-94.
62. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58:380-5.
63. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772-6.
64. Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:1673-7.
65. Zouhair A, Ozsahin M, Schneider D, et al. Invasive bladder carcinoma: a pilot study of conservative treatment with accelerated radiotherapy and concomitant cisplatin. Int J Cancer 2001;96:350-5.